|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO00438038X |
003 |
DE-627 |
005 |
20230425171230.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2022 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)WHO00438038X
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2017-002208-28-DE
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)D6185C00001
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy.
|b An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON). - HUDSON
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-11-2017, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Patients with non-small cell lung cancer (NSCLC) MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2022) vom: 30. Mai
|
773 |
1 |
8 |
|g year:2022
|g day:30
|g month:05
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002208-28
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2022
|b 30
|c 05
|